



National Institutes of Health/ NCI  
9609 Medical Center Drive, Suite 530  
Rockville, MD 20852  
Office (240) 276-5530  
Facsimile (240) 276-5504

July 31, 2017

James Love  
Knowledge Ecology International  
1621 Connecticut Avenue, Suite 500  
Washington, DC 20009  
(202)332-2670  
James.love@keionline.org

**SUBJECT:** KEI Comments in Regards to 82 FR 31783, "*Prospective Grant of Exclusive Patent License: Composition and Methods for Delivering Inhibitory Oligonucleotides for the Treatment of Pancreatic Cancer*" notice – Prospective Exclusive Patent License to VeriLuce Therapeutics

Dear Mr. Love,

Thank you for providing KEI comments to the recent *Federal Register* Notice referenced above regarding the National Institute on Aging's proposed intent to grant an Exclusive Patent License to VeriLuce Therapeutics. Prior to posting a notice for a proposed grant of an Exclusive Patent License, the National Institute of Health (NIH) determines that the criteria set forth in 37 CFR 404.7 have been satisfied with respect to granting the organization an exclusive license of the Government's intellectual property in the field of use as specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We consider all comments prior to negotiating the proposed license and will consider your comments.

Best regards,

Surekha Vathyam, Ph.D.  
Senior Technology Transfer Manager,  
National Cancer Institute Technology Transfer Center  
9609 Medical Center Dr., Room 1E-530, MSC 9702  
Rockville, MD 20850-9702  
Phone: 240-276-5530  
Email: vathyams@mail.nih.gov